Razoxane in the treatment of psoriatic patients resistant to or intolerant of PUVA, methotrexate and etretinate.

Thirty-six psoriatic patients resistant to or intolerant to PUVA, methotrexate and/or etretinate were treated with razoxane (ICRF 159) and EDTA derivative with antimitotic effects. The drug is highly effective in cutaneous and arthropathic psoriasis. Razoxane is well tolerated and appears to be free of hepatotoxicity.

[Tissue immunology in psoriasis. I. Changes in the immunologic mechanism caused by methotrexate].

To evaluate the posibility of detecting immunological alterations in psoriasics after MTX's treatment, lymphocyte culture was used, following Nowell's techniqe with slight modifications. There were no significant differences in blastic response between psoriasic patients and normals. Important variations were not observed in blastogenesis, after three and six weeks of MTX'S treatment, in the group of patients without previous medication.